The pure antiandrogen ru 23908 (anandron®), a candidate of choice for the combined antihormonal treatment of prostatic cancer: A review

@article{Raynaud1984ThePA,
  title={The pure antiandrogen ru 23908 (anandron{\textregistered}), a candidate of choice for the combined antihormonal treatment of prostatic cancer: A review},
  author={Jean Pierre Raynaud and Claude Bonne and Martine Moguilewsky and F. A. Lefebvre and Alain Bélanger and Fernand Labrie},
  journal={The Prostate},
  year={1984},
  volume={5}
}
The nonsteroidal antiandrogen RU 23908 (AnandronR) weakly interacts with the prostatic cytosolic androgen receptor and shows a fast dissociation rate. When administered to immature castrated rats up to the daily dose of 100 mg/kg, it is devoid of any androgenic activity but efficiently blocks the growth‐promoting activity of androgens on ventral prostate and seminal vesicle weight, thus showing the characteristics of a pure antiandrogen. In intact animals, on the other hand, the antiandrogen… 
Pharmacology of an antiandrogen, anandron, used as an adjuvant therapy in the treatment of prostate cancer.
TLDR
Animal experiments confirm that anandron can counteract the effect of adrenal androgens and inhibit the LHRH analog-induced initial increase in androgen ("flare-up") and decrease prostate weight in rats castrated either surgically or by buserelin or DES.
Effect of a nonsteroidal antiandrogen, anandron, on the reproductive system and fertility in male rats.
TLDR
The results suggest that the peripheral antiandrogenic potency of Anandron in intact animals is insufficient to completely neutralize the elevated levels of androgens.
Pharmacology of antiandrogens and value of combining androgen suppression with antiandrogen therapy.
TLDR
Nilutamide counteracts the trophic effect of adrenal androgens left intact by castration, which can only be suppressed by treatments that also suppress corticoid synthesis, and has been shown in the rat treated with buserelin.
Effect of the antiandrogen, WIN 49,596, on the descent of the testis in the male rat.
TLDR
While treatment with WIN inhibited the weights of the ventral prostate, seminal vesicles and penis, the drug only caused a 19% inhibition in the descent of the testes when compared to the control group, suggesting that other factors possibly working in tandem with androgens play a predominant role in testicular descent in the rat.
Antihormonal activities of 5α-reductase and aromatase inhibitors
TLDR
The results obtained may permit the formulation of the following conclusions: the conversion of testosterone to its 5α-reduced metabolites occurring in the neuroendocrine structures may represent an essential step for the appearance of the inhibitory feedback effect testosterone exerts on LH secretion.
How the study of the biological activities of antiandrogens can be oriented towards the clinic.
TLDR
The biological strategy that has led to the selection of a systemic and a topical antiandrogen has consisted in successively performing in vitro assays which measure an effect at a specific level in the mechanism of anti androgen action, e.g. interaction with the androgen receptor.
Efficacy and advantages in the use of low doses of anandron and estrogen combination in the treatment of prostate cancer
TLDR
It is suggested that low doses of Anandron and estrogen can effectively be combined as a complete androgen counteracting therapy for hormone‐dependent prostatic carcinoma with minimal undesired side effects.
Endocrine profile of Win 49596 in the rat: a novel androgen receptor antagonist.
TLDR
The data indicate that Win 49596 is a peripherally selective antiandrogen that has minimal effects on circulating testosterone levels and is devoid of hormone agonist activity, which may be useful for the treatment of androgen dependent conditions such as benign prostatic hyperplasia and prostatic cancer.
Pharmacological and clinical studies of the antiandrogen Anandron.
TLDR
As shown in 4 different double blind studies performed in stage D2 prostrate cancer patients, the combination of Anandron with surgical or chemical castration enhanced the beneficial effects of castration alone and thus seems a step forward in the hormonal treatment of prostatic carcinoma.
Antiandrogenic agents as monotherapy in advanced prostatic carcinoma
TLDR
Proper stratification of patients at entry into such studies with documentation of various prognostic factors will add statistical value and enable physicians to draw better conclusion on the relative efficacy of these agents.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 20 REFERENCES
Combined long‐term treatment with an LHRH agonist and a pure antiandrogen blocks androgenic influence in the rat
TLDR
The present data show that blockage of the Δ4‐steroidogenic pathway induced by treatment with an LHRH agonist prevents the escape phenomenon observed during long‐term treatment with a pure antiandrogen, and permits maximal inhibitory effects of the two treatments on secondary sex organ weight.
Action of a non-steroid anti-androgen, RU 23908, in peripheral and central tissues.
Abstract RU 23908 (5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl]-2,4-imidazolidinedione) is a non-steroid anti-androgen with potent peripheral and central activity. In the rat, it inhibits
Additive inhibitory effects of treatment with an LHRH agonist and an antiandrogen on androgen-dependent issues in the rat
Combined treatment of adult male rats with the LHRH agonist, [D-Ser(TBU)6, des-Gly-NH2(10)]LHRH ethylamide, and a non-steroid antiandrogen, RU 23908, led to a rapid and marked atrophy of the ventral
Antifertility effects of LHRH agonists in the male rat and inhibition of testicular steroidogenesis in man.
TLDR
Preliminary data obtained in patients with cancer of the prostrate show inhibition of both testosterone and dihydrotestosterone plasma levels with a temporary loss of diurnal cyclicity, suggesting the potential use of LHRH agonists in male contraception and for the treatment of cancer ofThe prostrate.
New approach in the treatment of prostate cancer: Complete instead of partial withdrawal of androgens
TLDR
The present data show that complete withdrawal of androgens by combined hormonal therapy with the LHRH agonist (or castration) and a pure antiandrogen leads to a positive objective response in more than 95% of cases as opposed to 60%‐70% as reported by many groups using the previous partial hormonal therapy.
On the Mechanism of the Anti-androgenic Action ofFlutamide (α-α-α-Trifluoro-2-methyl-4'-nitro-m-propionotoluidide)in the Rat
TLDR
Both flutamide and cyproterone acetate fully antagonized the effect of testosterone on maintaining prostate and seminal vesicle weights in these rats and markedly inhibited 3H-testosterone uptake and retention by prostate and prostate nuclei when labeled androgen was given 3 hr following the last dose of the drug.
Screening for anti-hormones by receptor studies.
TLDR
The primary advantage of running studies in parallel on several receptors resides in the possibility of classifying the anti-hormones according to whether they possess affinity for a given receptor, thus providing a criterion for the selection of highly specific compounds virtually devoid of hormonal side-effects.
RU 16117, an orally active estriol-like weak estrogen.
TLDR
Since RU 16117 transiently occupies available estrogen binding sites, it can prevent the full response of estradiol and acts as an estrogen antagonist on the above parameters and also on DMBA-induced mammary tumors in the rat.
Inhibitory Effect of LHRH and Its Agonists on Testicular Gonadotrophin Receptors and Spermatogenesis in the Rat
Treatment of adult male rats with the potent LHRH agonists [D-Leu6, des-Gly-NH210]LHRH ethylamide or [D-Ala6. des-Gly-NH210]LHRH ethylamide led to a marked reduction of testicular LH and prolactin
Steroid hormone receptors and pharmacology.
TLDR
Highly specific ligands derived from this screening system are being used not only as drugs but as tools to study the physiological regulation of hormone receptors in both peripheral and central target tissues.
...
1
2
...